No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland, Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
Seeking Alpha / 5 hours ago 1 Views
Comments